Why first-generic launches decide who leads a market

The first generic to reach a market sets its price point, takes the formulary listings, and becomes the name physicians remember.

The window is the registration, not the molecule

By the time a patent lapses, every distributor in the region knows it. The race is not discovering the opportunity — it is having a dossier ready and a regulatory team that files on the first eligible day. This is why we keep a dedicated registration team in every country we operate in rather than routing paperwork through a regional hub.

What being first actually buys

A first generic typically enters at a discount to the originator but well above the floor the third and fourth entrants will later fight over. Hospitals and insurers form their reference prices around the early entrants. Tender committees shortlist products they have already seen supplied reliably.

The discipline behind it

Our research team shortlists molecules eighteen to thirty months ahead of patent expiry, weighing originator volumes, therapy-area growth and the practical question every launch stands on: can the supply base deliver consistent batches at the volumes the market will demand on day one?

First is a strategy, not an accident.